Core Viewpoint - Aclarion, Inc. has adopted a limited duration stockholder rights plan to protect stockholders' long-term value and prevent any person or group from gaining control without appropriate compensation [1][2]. Summary by Sections Rights Plan Overview - The Rights Plan is effective immediately and will expire in one year, specifically on March 18, 2027 [1][10]. - It aims to ensure that the Board has adequate time to make informed decisions in the best interest of Aclarion and its stockholders [2]. Applicability and Intent - The Rights Plan applies equally to all current and future stockholders and was not adopted in response to any specific acquisition proposal [3]. - It is designed to deter unauthorized control attempts while allowing the Board to consider fair offers [3]. Rights Distribution - Aclarion declared a dividend distribution of one preferred stock purchase right for each share of common stock and each Rights-Eligible Warrant outstanding as of March 30, 2026 [4]. - Each right will attach to shares of common stock and Rights-Eligible Warrants, initially not being exercisable [5]. Rights Exercise Conditions - Rights become exercisable if an entity or person acquires 10% or more of the common stock without Board approval [7]. - Existing ownership above the threshold prior to the Rights Plan announcement is grandfathered, but any increase in ownership will trigger the rights [7][9]. Rights Value and Exchange - If exercisable, each right allows the holder to purchase shares of Series D Junior Participating Preferred Stock at a cash price of $14.00 per right [6]. - In the event of a triggering ownership threshold, rights holders (excluding the triggering party) can receive shares of common stock valued at twice the exercise price [8]. Legal and Company Information - Goodwin Procter LLP is serving as legal counsel for Aclarion [11]. - Aclarion is a healthcare technology company focused on optimizing clinical treatments using Magnetic Resonance Spectroscopy and other advanced techniques [12].

Q4/FY'25 Earnings Presentation February 26, 2026 Forward-Looking Statements Statements in this release that are not historical are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, include, but are not limited to, statements regarding: our business strategy; anticipated future operating results and operating expenses, cash flows, ca ...

Core Viewpoint - Endeavor Investor Group criticizes Mawson Infrastructure Group's adoption of a stockholder rights plan, viewing it as a move to entrench management rather than address operational underperformance and shareholder value destruction [2]. Group 1: Rights Plan and Shareholder Impact - Mawson's implementation of the Rights Plan is seen as a tactic by management to protect themselves while harming shareholders by limiting constructive feedback and accountability [2]. - The number of outstanding shares has increased to approximately 5.3 million, nearly quintupling since the last 10-Q filing in November, indicating significant shareholder dilution [2]. - The company's stock price has been in decline, now worth a fraction of its value from a year ago, reflecting the negative impact of management's actions and the Board's oversight failures [2]. Group 2: Call for Change and Engagement - Endeavor emphasizes the need for Mawson to engage with shareholders and transparently discuss capital plans instead of resisting shareholder inquiries [2]. - The group advocates for new perspectives, stronger governance, and a disciplined approach to value creation at Mawson [3]. - Endeavor encourages all Mawson shareholders to reach out for open dialogue regarding the urgent need for change [3]. Group 3: Endeavor's Background - Endeavor Investor Group focuses on high-performance compute and digital asset infrastructure, comprising several affiliated entities [4]. - The group has experience in developing and financing energy-intensive compute and digital asset facilities, as well as power procurement and regulatory strategy [7].

Core Viewpoint - Bimini Capital Management, Inc. has amended its Rights Agreement to extend its expiration date and adjust the purchase price, aiming to preserve stockholder value and protect its net operating loss carryforwards [1][2][3]. Group 1: Rights Plan Amendment - The Board of Directors adopted the First Amendment to the existing Rights Agreement, extending the expiration date from December 21, 2025, to December 21, 2030, and increasing the purchase price from $4.76 to $10.20 [1]. - The Rights Plan is intended to safeguard stockholder value and the value of tax assets, specifically net operating loss carryforwards (NOLs), which amounted to approximately $253.9 million as of September 30, 2025 [2]. - The increase in the purchase price is designed to enhance potential dilution for stockholders triggering rights under the plan, thereby reducing the likelihood of an "ownership change" as defined by Section 382 of the Internal Revenue Code [3]. Group 2: Stockholder Approval and Future Actions - The First Amendment will be submitted for stockholder approval at the 2026 annual meeting, with automatic termination of the amendment set for June 30, 2026, if approval is not obtained [4]. - A detailed summary of the First Amendment will be included in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission [5]. Group 3: Company Overview - Bimini Capital Management, Inc. primarily invests in residential mortgage-related securities issued by government-sponsored entities such as Fannie Mae, Freddie Mac, and Ginnie Mae [6]. - The company also manages Orchid Island Capital, Inc., a publicly-traded real estate investment trust, and Royal Palm Capital, LLC, both with similar investment strategies [7][8].

Financial Performance - Net sales increased to $155 million in Q3'25 from $109 million in Q3'24[16] - Adjusted EBITDA rose to $40 million in Q3'25, compared to $17 million in Q3'24[16] - Adjusted EBITDA margin improved to 26% in Q3'25 from 16% in Q3'24[16] - Diluted EPS was $010 in Q3'25, a significant improvement from $(035) in Q3'24[16] Sales and Production - The company saw increased sales volumes of AN (Ammonium Nitrate) and Nitric Acid in Q3'25 compared to Q3'24[8] - UAN (Urea Ammonium Nitrate) sales volumes also increased in Q3'25 compared to Q3'24[8] Market Conditions and Outlook - The company anticipates a strong market outlook for both fertilizer and industrial end markets into 2026[9] - Demand for industrial products is robust, supported by strong gold and copper prices[10, 11] - Strong fertilizer pricing is expected to continue, driven by ammonia supply disruptions and strong demand[13, 15] Balance Sheet and Liquidity - The company's cash and short-term investments totaled $152 million as of September 30, 2025[22] - Total debt was $448 million as of September 30, 2025[22] - Net debt to TTM (Trailing Twelve Months) Adjusted EBITDA was 20X[22]

Core Viewpoint - Eagle Pharmaceuticals, Inc. has amended its limited duration stockholder rights plan to extend its duration by one year to October 30, 2026, in response to significant dislocation in the trading price of its common stock [1][2] Summary by Sections Rights Plan Amendment - The amendment aims to increase potential dilution for any Acquiring Person if the Rights Plan is triggered, allowing stockholders to realize long-term value and reducing the likelihood of control by any person or group without proper compensation [2][4] - The Rights Plan will automatically expire on October 30, 2026, unless redeemed or exchanged earlier by the Company [4] Acquisition and Control - The Board did not adopt the extension in response to a specific takeover threat and retains the ability to engage with parties or accept acquisition proposals if deemed in the best interests of the Company and its stockholders [3] Rights Plan Details - The Rights become exercisable if an Acquiring Person acquires 10% or more of the outstanding common stock (15% for passive institutional investors) [4] - Stockholders above the threshold at the initial announcement are grandfathered but cannot increase ownership without triggering the Rights Plan [4] - Each Right allows the holder to purchase additional shares at $20.00, with a market value of twice the exercise price [4] Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company focused on developing innovative medicines, with a pipeline addressing underserved therapeutic areas [6]

Q2'25 Performance Highlights - Increased total sales volumes by 6% compared with Q2'24, driven by UAN and AN sales[10] - Net sales increased to $151 million in Q2'25 from $140 million in Q2'24[17] - Adjusted EBITDA was $38 million in Q2'25, compared to $42 million in Q2'24[17] - Adjusted EBITDA margin decreased to 25% in Q2'25 from 30% in Q2'24[17] - Diluted EPS was $004 in Q2'25, compared to $013 in Q2'24[17] Balance Sheet and Capital Allocation - Reduced debt by $32 million[10] - Cash and short-term investments were $125 million as of June 30, 2025, compared to $216 million as of June 30, 2024[23] - Total debt was $453 million as of June 30, 2025, compared to $486 million as of June 30, 2024[23] - Net debt to TTM Adjusted EBITDA was 27x[23] El Dorado CCS Project - The El Dorado low carbon ammonia project is progressing towards a 2H'26 startup[10]